ArticleEuropean journal of epidemiology2026
Survival in children and adolescents with life-limiting conditions-a nationwide cohort study.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
There is an increasing prevalence of children and adolescents with life-limiting conditions (LLC) with potential need for supportive and palliative care, but their survival has never been investigated. We aimed to investigate the survival of children and adolescents with LLC and potential factors for poor prognosis through a registry-based nationwide cohort study. We included all patients aged 0-21 years, born in Denmark and diagnosed with an LLC between January 1, 1995 and December 31, 2021. Kaplan-Meier survival curves were plotted across disease groups. Regression models with 1-year and 10-year restricted mean survival time as outcomes were used to investigate factors for poor prognosis including child sex, age, parental education and diagnostic period. We identified 102,793 children and adolescents with a total of 116,599 LLC (10.8% had >1 diagnosis). Median follow-up time was 9.85 years (interquartile range 5.15, 16.05) with 5728 deaths. Most deaths occurred within one year of diagnosis. Overall 1-year and 10-year survival rates were 95.6% and 94.5% respectively. In children <1 year, the poorest overall survival was seen in children with metabolic diseases before 2010 and neurologic diseases after 2010. In children ≥1 year, the poorest overall survival was seen in those with malignancy diseases regardless of diagnostic period. Children <1 year, with multiple concurrent diagnoses, parents with shorter educations, and diagnosed before 2010 had the shortest survival times. Most children and adolescents with LLC live for many years with illness. Thus, it is important to clarify their need for supportive and palliative care, along the illness trajectory.
Indexed as
Identifiers
42776467What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.